Overexpression of eIF4E gene in acute myeloid leukemia and its relation with disease progression.
10.7534/j.issn.1009-2137.2013.02.007
- Author:
Yin-Di JIANG
1
;
Yu-Hong LU
;
Shao-Hua CHEN
;
Kang-Er ZHU
;
Xue-Li ZHANG
;
Zhi YU
;
Jun ZHONG
;
Tao ZHANG
;
Geng-Xin LUO
;
Jie CHEN
;
Huan-Yu PAN
;
Yan LI
;
Lian-An QIN
;
Yang-Qiu LI
Author Information
1. Department of Hematology, Affiliated First Hospital, Jinan University, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Child;
Disease Progression;
Eukaryotic Initiation Factor-4E;
genetics;
Female;
Gene Expression;
Humans;
Leukemia, Myeloid, Acute;
genetics;
pathology;
Male;
Middle Aged;
Real-Time Polymerase Chain Reaction;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(2):296-299
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to detect the expression level of eIF4E gene in patients with non-treated, remission and non-remission/relapse acute myeloid leukemia (AML), and other non-malignant haematologic diseases so as to analyze and reveal the relationship of eIF4E gene expression with AML progression. SYBR Green I RT-PCR was used to assay the expression level of eIF4E mRNA extracted from bone marrow mononuclear cells in 30 patients with AML (6 in M2, 5 in M3, 8 in M4, 10 in M5, 1 in M6) and 20 patients with non-malignant hematologic diseases. The β2-microglubin(β2M) was used as internal reference and the formula 2(-ΔCt)×100% was applied to calculate the expression level of eIF4E gene. The results showed that the eIF4E expression level (7.098 ± 5.544)% in patients with non-treated and non-remitted/relapsed AML was significantly higher than that in patients with remission (0.964 ± 0.312)% (P < 0.01) and non-malignant hematologic diseases (0.248 ± 0.163)% (P < 0.01). There was no difference between latter two group patients, even though the expression level of eIF4E gene in patients with M4 and M5 was higher. As compared with non-malignant hematologic diseases, the expression level of eIF4E gene of patients with remission patients showed no significant difference. It is concluded that the over-expression of eIF4E gene has been found in patients with AML, and its level obviously decreases along with remission of disease, thus the eIF4E gene may be a surveillance parameter for disease progression.
